Amplia Therapeutics Limited
@amplia_therapeutics
Melbourne, Victoriahttp://www.ampliatx.com Pharmaceutical ManufacturingOverview
About Amplia Therapeutics Limited
Amplia Therapeutics Limited (ASX: ATX; OTCQB: INNMF), a pharmaceutical company based in Melbourne, Australia, focuses on development of focal adhesion kinase (FAK) inhibitors for the treatment of cancer and chronic fibrotic diseases.
The company's lead product is narmafotinib (AMP945), a best-in-class inhibitor of FAK, currently undergoing clinical trials in advanced pancreatic cancer. Data from the Phase 1b/2a ACCENT trial run in Australia and Korea has been very positive and a new clinical trial is now opening in the US and Australia under an open IND.
Additional opportunities in other cancers such as ovarian cancer, and in fibrotic diseases such as idiopathic pulmonary fibrosis, are also being explored based on promising preclinical data.
Narmafotinib has Orphan Drug Designation and Fast-Track Designation from the US FDA for pancreatic cancer.
The company's lead product is narmafotinib (AMP945), a best-in-class inhibitor of FAK, currently undergoing clinical trials in advanced pancreatic cancer. Data from the Phase 1b/2a ACCENT trial run in Australia and Korea has been very positive and a new clinical trial is now opening in the US and Australia under an open IND.
Additional opportunities in other cancers such as ovarian cancer, and in fibrotic diseases such as idiopathic pulmonary fibrosis, are also being explored based on promising preclinical data.
Narmafotinib has Orphan Drug Designation and Fast-Track Designation from the US FDA for pancreatic cancer.